effect of valsartan / amlodipine on LVDD

Phase 2

Recruiting

• Conditions: I50.3; Condition 1: hypertension. Condition 2: Left ventricular diastolic dysfunction.; Essential (primary) hypertension; Diastolic (congestive) heart failure

• Registration Number: IRCT20201102049232N1
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

All patients with newly diagnosed hypertension
Patients with hypertension with evidence of echocardiographic LVDD

Exclusion Criteria

Taking ARB or ACEI drugs in the last three months
Left Ventricular Ejection Fraction less than 50%
Major valvular heart disease
Previous allergy or contraindication to the use of the studied drugs
Serum creatinine above 1.5
Lack of blood pressure control with the studied drugs
Patient dissatisfaction with continuing the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eft ventricular diastolic dysfunction. Timepoint: At the beginning of the study and 6 months after starting medication for hypertension. Method of measurement: Trans thoracic echocardiography.